Leigh Brody and Dominik Leisi have joined Albion Capital to work on the life science investment team for UCL Technology Fund.
Albion Capital has appointed Leigh Brody and Dominik Leisi to the life science investment team for University College London (UCL)’s Technology Fund.
The firm has hired Brody as an investment manager, while Leisi has joined the fund as a part of a one-year secondment from UCL’s commercialisation company, UCL Business (UCLB).
Brody has 10 years’ of life sciences experience and was most recently an executive director of platform strategy at biopharmaceutical company Quell Theraputics, where she led on technology development and platform strategy.
She also worked at gene editing software developer Desktop Genetics between 2015 and 2019, as director of genomics as well as a chief scientific officer.
Leisi is currently a senior business manager at UCLB, where he has worked since 2015. He also was previously a technical lead at life sciences company BTG and a product development engineer at dental implant maker Nobel…
